 |
|
|
| |
CROI 2016 - Themed Discussion: Rants About HCV RAVS
|
| |
| |
I have included links to 2 talks -
(1)Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance
Wei Huang, Monogram Biosciences, South San Francisco, CA, United States
(2)Retreatment with Harvoni of 34 Patients Treated Only for Short-Duration 4-6 Weeks with Harvoni in SYNERGY Trial, Eleanor Wilson, NIAID SYNERGY Trial
WEBCAST for Dr Huang's
talk:http://www.croiwebcasts.org/console/player/29510?mediaType=audio&
She reported on an analysis of prevalence & drug susceptibility to NS5A resistance mutations (RAVs) on 973 samples submitted to Monogram for routine NS5A resistance testing.
Retreatment with Harvoni of 34 Patients Treated Only for Short-Duration 4-6 Weeks with Harvoni in SYNERGY Trial
Many of these patients had high level NS5A resistance but SVR Rates in the retreatment study were 85-90%
WEBCAST for Dr Wilson's
talk:http://www.croiwebcasts.org/console/player/29514?mediaType=audio&
|
| |
|
|
|
|
|
